WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.

WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...

wallstreetcn13minutes ago

Bide Pharmaceutical's net profit in 2024 increased by 7.17% year-on-year, with the Overseas market becoming the growth engine.

In 2024, Bid achieved an annual revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; the net income attributable to the parent company's shareholders was 0.117 billion yuan, a year-on-year increase of 7.17%; the company stated it will continue to optimize the product structure, deepen its global layout, and increase R&D investment to respond to changes in the industry technology.

cls.cnApr 24 00:29 ET

The chairman of Sanbo Neuroscience has been taken into custody for investigation. Just five days ago, he was still presiding over the Board of Directors meeting | Quick read announcement.

① Today, Sanbo Neuroscience announced that one of its actual controllers and the Chairman, Zhang Yang, has been detained and is under investigation; ② The specific reasons and time for lifting the detention have not been detailed in the announcement. Five days ago, Zhang Yang was still present at the company meeting room, where he convened and chaired the Board of Directors.

cls.cnApr 21 11:28 ET

Shanghai Medicilon Inc.'s revenue in 2024 declined by over 20%, with losses further expanding.

① Affected by multiple factors such as the slowdown in investment and financing in the Industry, intensified market competition, and contraction in domestic market demand, Shanghai Medicilon Inc. is expected to continue expanding its losses to 0.331 billion yuan in 2024; ② By region, the domestic market is heavily impacted by the reduction in R&D investment from local pharmaceutical companies and price wars, becoming the main drag on performance; the Overseas market, although maintaining growth, has seen increased costs due to new experimental facility investments, squeezing profit margins.

cls.cnApr 21 11:11 ET

Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.

As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.

cls.cnApr 16 20:31 ET

The Equity Transfer of the symbol has not been delivered, and Bidu Medicine terminates the significant Assets reorganization.

① Regarding the termination of the merger and acquisition, the company stated that the failure to complete the delivery of 100% equity of the target company as expected has resulted in the inability to achieve the purpose of this Trade. Liu Weidong stated that the termination of this acquisition will not affect the company's established Global Strategy layout; ② Bid Pharma has completed the construction of the R&D center and the upgrade of storage facilities in the USA market last year.

cls.cnApr 15 08:33 ET